Connect with us

Press Release

New in crypto investment? Let’s get started with Bit.Store where it only takes 3 steps to get cryptos

Published

5 years ago

on

Investing in digital currency has become a trend

With the new record Bitcoin (BTC) price reached earlier this year and the wave of price surge of DOGE and SHIB led by Elon Musk, digital currency has gradually attracted outsiders. It has become one of the major topics in global investment trend. Players including Facebook, national-level digital currencies, commercial companies, tournament games, Tesla, etc. have all begun to get involved in digital currencies.

Although BTC has fallen from the highest price of $64,000, in fact, many users’ enthusiasm for BTC or other cryptos has not diminished at all. In the tide of digital currency, insiders may be familiar with the concepts and tricks of DeFi, IDO, GameFi, NFT, etc., but outsiders still have difficulties getting started with even the most basic transaction operation as buying or selling.

According to Trading View’s data: The total market value of cryptocurrencies has risen from US$6,617 million on March 1, 2014 to US$2,101 trillion as of date (August 24, 2021). This shows the rapid development of the digital currency industry. Generally speaking, the simplest investment strategy is to buy mainstream cryptos that have endured the test of time, such as Bitcoin and Ethereum. Although the fluctuations are relatively flat, but the return on investment still exceeds any other investment product on the market.

In addition, advanced players will perform position management, and will test invest in some altcoins on platforms such as Binance, Coinbase, and Huobi. More advanced players will perform lock-up mining and various activities like farming and panic buying etc., but these tricks are extremely difficult for novice users. In this case, a simple, easy-to-use and safe software is demanded with urgence. Therefore, Bit.Store comes to help.

Bit.Store makes it easier to buy digital currency

According to its official briefs, Bit.Store is a purchase platform of digital assets with the characteristics of safety, convenience, and cross “fiat-crypto”. It’s becoming popular in Southeast Asia, Europe and other regions, and in particular, has become the most popular platform for novice crypto investors in Indonesia. Meanwhile, Bit.Store is focused on enhancing its attribute for social networking, ready to fully embrace the web3.0 era, helping novice users build a decentralized community, and establish efficient information exchange channels for digital assets.

Briefly, through Bit.Store platform, novice investors can directly buy cryptos with fiats, for instance, buying USDT or BTC with U.S. dollars. And there is no need to worry about security and legal issues, which will be specifically referred to in the following.

As a matter of fact, in this field, there are already many competitors. In the present business environment, where there are people, there will be always competition. Apparently, PayPal and CashApp are outstanding ones in the sector. However, it is undeniable that they also have defects. For example, PayPal purchases bitcoins. The handling fee of 2%-5% is rarely mentioned by CashApp in the Asian region. Complicated operation procedures, long waiting confirmation time, asset-light publicity coverage, high handling fees, etc., are all the obstacles that keep users from entering the field of digital currency investment, thus slow down the expanding of digital currency that was originally meant to improve asset utilization and efficiency.

Before the launch of Bit.Store, we have done sufficient research on the market and optimized all these problems.

Handling fee: Bit.Store charges only 2% handling fee.

Operation: Once you have the actual experience on Bit.Store, you will find that there are only three steps to go through when buying bitcoin, namely, check the transaction curve of the price, choose to buy, choose the payment method, and there you go. No matter you’re a novice or veteran user, you can enjoy the ultimate experience.

Security: Bit.Store’s assets are entrusted to Coinbase, one of the world’s top three trading platforms, and Cobo, Asia’s leading cryptocurrency wallet, which should be familiar to longtime users. Coinbase, in particular, is the dominant trading platform right now. In addition to selecting reliable partners, Bit.Store also invites PWC auditors to conduct regular audits, which, combined with its active compliance with laws and regulations, makes Bit.Store’s security level almost equal to that of asset managers in traditional finance.

Development Plan: The history of Nokia tells us that if we do not move forward, we will be abandoned by the time. This is especially true in the domain of blockchain. As a result of the rapidly changing market and industry hit, we must stay humble and stay hungry, if we want to achieve long-term growth. In this regard, Bit.Store is not only a fiat trading platform, but also a UGC/PGC community, which can be envisaged as the Bilibili.com in the field of digital currency. Users can freely discuss issues about cryptos and help beginners understand investment skills. Blockchain is based on consensus and trust, which is also implemented by Bit.Store as a core guidance. Of course, there will be incentives for referrals and those who are active in answering questions in the community.

Only with a solid foundation we can have a bright future

Similar to PayPal, Alipay is very popular in China, while almost everyone has an account of PayPal in Europe and America. In Southeast Asia, where Bit.Store is well accepted, it becomes a promising region. Especially in recent years, due to geographical location and development advantages, Southeast Asia shows a tendency of increasingly expanding young population. Young people tend to accept new things due to their curiosity. According to a survey, it shows that 80% of the respondents said they were aware of cryptocurrency, 53% expressed the interest to invest, 17% of them are even very knowledgeable about cryptos.

Thanks to the huge number of young people, it has laid a good foundation for Bit.Store’s business expansion and development. In addition, the regulatory environment in Southeast Asia is also very friendly, with well-established channels. At the same time, it is also sophisticated for international communication in the region. Although it is slightly less developed than Europe and the United States, but as for the internet infrastructure and its leading economic basis, users in Southeast Asia tend to be more open towards cryptocurrencies.

It is noted that successful transactions between fiat and crypto currencies often require more than just users and technology. The factor of government relations is often the most important element. It is understood that Bit.Store attaches much more importance to this area than what you can imagine. The cooperation has been rolled out with nearly 40 payment companies in over 20 countries and regions, with one international bank and one international payment institution. Right now there are payment licenses available in Hong Kong, the Philippines, Singapore, as well as many countries and regions in the European Union.

According to official data, Bit.Store has already attracted 200,000 users worldwide since its launch about a year ago, with some 50,000 daily active users. The sharp increase in the number of users shows that there is a looming demand in the market in this area, and the surge in growth should be due to its full preparation. In the aspect of social functions, as mentioned above, it is an important part of Bit.Store’s development plan. In the traditional world, money and information are transferred separately, while in the blockchain world, value and information are combined. There is no doubt that trust is a must. With a brand-new business module, we have the widest economic moat to make the service to be adored and recognized by users.

Bitcoin was created about 10 years ago. However, in those days no one could imagine that the value of Bitcoin would reach 60,000 US dollars ten years later. In this sense, the future always means something you can’t imagine. Nowadays, Bitcoin is no longer a topic discussed in a small circle. Bitcoin and other digital currencies have got their best chance to grow, thus they have become a rising star in the global investment field. At the same time, blockchain technology has also been on the top of the R&D agenda in many countries.

Probably some people are still watching, while some people have already quit. Perhaps some people are eager to get started, while some people get frustrated about it. In any case, the future development is bound to go forward. And if you didn’t find a way to get onboard the bandwagon, then hop on Bit.Store.

About Author

Alex Jacob

Alex Jacob is a literature author. He was born in Chicago. Alex passion is writing news articles. He writes number of articles and published it.

See author's posts

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.

Related Topics:
Continue Reading

Press Release

RedHill Announces Transformational Acquisition of Commercialization Rights to Ferring’s Rebyota® and Clenpiq®

Published

2 minutes ago

on

September 1, 2026

By

Raleigh, United States, September 1st, 2026, FinanceWire

Together with the previously announced Talicia strategic divestiture, the acquisition from Ferring of commercialization rights to two larger, proprietary, established gastrointestinal (GI) FDA-approved drugs that together generated approximately $37.5 million in 2025 net sales, completes a major strategic repositioning of RedHill’s commercial GI business

The divestiture of Talicia and the acquisition of the new GI products from Ferring create a catalyst for commercial growth through a materially larger GI business under RedHill’s control, with a significantly stronger liquidity position and provides additional growth and expansion opportunities

Under the terms of the agreement, RedHill obtained the exclusive commercialization rights for an upfront payment to Ferring of $12 million plus potential future milestones and tiered royalties.

The $12 million upfront payment is fully funded through the previously announced $18 million Talicia divestment, with RedHill securing exclusive global and U.S. commercialization rights to Ferring’s Rebyota and Clenpiq, respectively – two synergistic, revenue-generating, FDA-approved GI drugs

Rebyota is a proprietary, first and only single-dose FDA-approved Fecal Microbiota Transplant (FMT for prevention of recurrent C. diff infection (rCDI). FDA-approved in 2022 and Health Canada-approved in 2025, Rebyota, was granted a Breakthrough Therapy and received Orphan Drug designations and generated approximately $16.9 million in 2025 U.S. net sales

Proprietary Clenpiq, a ready-to-use (no mixing required) low-volume bowel preparation on the U.S. market, generated $20.6 million in U.S. 2025 net sales with minimal promotion 

RedHill Biopharma Ltd. (Nasdaq: RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company, today announced the transformational acquisition of exclusive global and U.S. commercialization rights to Rebyota and Clenpiq, from Ferring Pharmaceuticals (“Ferring”), as part of Ferring’s ongoing strategic refocusing.

Dror Ben-Asher, RedHill’s Chief Executive Officer, said: “We have executed a clear strategic sequence. We have monetized Talicia for $18 million cash upfront, plus $35 million in potential upside, used $12 million to secure commercialization rights to two established, proprietary, FDA-approved gastrointestinal drugs, that collectively generated approximately $37.5 million in U.S. net sales in 2025, and emerged with a materially larger, fully controlled commercial business and a stronger liquidity position. Rebyota and Clenpiq are expected to generate a positive cash contribution to RedHill. This, combined with RedHill’s experienced and lean commercial team and proven development capabilities, creates a scalable foundation for further growth, including additional acquisition of complementary revenue-generating products.” Mr. Ben-Asher added: “We thank Ferring for a smooth process to date and look forward to a successful collaboration.”

Under the terms of the agreement, RedHill obtained an exclusive global commercialization license of Rebyota and an exclusive U.S. commercialization license of Clenpiq, for an upfront payment to Ferring of $12 million, plus tiered royalties on net sales and potential milestones. Ferring retains its Rebyota manufacturing facilities, and Ferring will continue to supply Rebyota through the term of the agreement.

“Rebyota is a first-in-class microbiota-based therapy for prevention of recurrent Clostridioides difficile (C. diff) infection (rCDI) in individuals 18 years of age and older following antibiotic treatment for rCDI. FDA-approved in 2022, it generated approximately $16.9 million in U.S. net sales in 2025 through its clinical profile, broad coverage and an established customer base of approximately 600 active accounts,” said Rick Scruggs, RedHill’s Chief Commercial Officer. “Clenpiq, a ready-to-drink low-volume bowel preparation on the U.S. market, delivered $20.6 million in net sales in 2025, with minimal promotion. Together the two assets give RedHill a significantly stronger commercial growth engine in both the U.S. and other new territories.”

C. diff (CDI) infection is a distressing and life-threatening condition – in developed countries it is the most common cause of healthcare-associated (HA) diarrhea. An estimated 3.6 million cases of CDI occur globally each year, including approximately half a million cases in the U.S. 30,000 Americans die every year due to CDI, with a global mortality rate of 1-in-10, rising to almost 1-in-3 in high-risk settings1. In the U.S., up to approximately 165,000 CDI cases result in one or more recurrences, indicating the need for use of prevention strategies.

Rebyota’s one-time administration, which requires no fasting, bowel prep or extended treatment timeframe, has demonstrated more than a 70% success rate at preventing rCDI. An aging population and accompanying increasing hospital-acquired vulnerabilities will likely increase this need. A streamlined ordering and reimbursement process is already in place for physicians, and broad and improving U.S. payer coverage means that 93% of lives have coverage including 43% with coverage after 1st recurrence.

Rebyota, which was granted, Breakthrough Therapy and Orphan Drug designations – with exclusivities and other patent protections that could run to 2036, provides multiple growth opportunities, including recent approval in Canada. The existing approvals also provide the potential for additional approvals in other territories.

Colonoscopy is the cornerstone of GI practice, with more than 15 million colonoscopies performed in the U.S. annually. This number is rising, with follow-up needed after noninvasive screening tests that yield a positive result, an aging population, and guidelines that recommend testing at age 45 instead of age 50, contributing to an increased need for colonoscopy. Bowel preparation is not a pleasant process and is often poorly performed.

Clenpiq is a ready-to-drink low-volume bowel prep. Clenpiq is readily available to patients and has broad commercial and government payer coverage: More than 108 million lives (63%) with unrestricted (no prior approval) have commercial coverage, including 57 million (33%) with preferred position. 23m lives (41%) of Medicare Part D lives have unrestricted access to Clenpiq, including 12m (21%) lives with preferred position5.

RedHill was advised by Morningstar Law Group and Greenberg Traurig LLP on this transaction.

About RedHill Biopharma  

RedHill Biopharma Ltd. (Nasdaq: RDHL) is a specialty biopharmaceutical company primarily focused on U.S. development and commercialization of drugs for gastrointestinal diseases, infectious diseases and oncology. RedHill promotes the FDA-approved gastrointestinal therapies Rebyota, for the prevention of recurrent C. diff infection (rCDI), and the bowel preparation treatment, Clenpiq. RedHill’s key clinical late-stage development programs include: (i) opaganib (ABC294640), a first-in-class, orally administered sphingosine kinase-2 (SPHK2) selective inhibitor with anti-inflammatory, antiviral, metabolic and anticancer activity, targeting multiple indications with a track record of U.S. government and academic collaborations intended for medical countermeasure development including for EVD, radiation exposure indications such as GI-Acute Radiation Syndrome (GI-ARS), a Phase 2/3 program for hospitalized COVID-19, and an ongoing Phase 2 study in prostate cancer in combination with darolutamide; (ii) RHB-102 (Bekinda), with a planned Phase 2 proof-of-concept study for GLP-1/GIP receptor agonist-associated GI intolerance, positive results from a U.S. Phase 3 study for acute gastroenteritis and gastritis, positive results from a U.S. Phase 2 study for IBS-D and potential UK submission for chemotherapy and radiotherapy induced nausea and vomiting. RHB-102 is partnered with Hyloris Pharmaceuticals (EBR: HYL) for worldwide development and commercialization outside North America; (iii) RHB-204, a next-generation optimized formulation of RHB-104, with a planned Phase 2 study for Crohn’s disease (based on RHB-104’s positive Phase 3 Crohn’s disease study results); and (iv) RHB-107 (upamostat), an oral broad-acting, host-directed, serine protease inhibitor with potential for pandemic preparedness, including COVID-19 and also targeting multiple cancer and inflammatory gastrointestinal diseases.

More information about the Company is available at www.redhillbio.com / X.com/RedHillBio.

Forward Looking Statements

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 and may discuss investment opportunities, stock analysis, financial performance, investor relations, and market trends. Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words, and include, among others, statements regarding the divestment of Talicia and the potential use of the proceeds of such sale; the expected benefits of the acquisition of commercialization rights to Rebyota and Clenpiq, the anticipated commercial growth and cash contribution from these products, expectations regarding market share growth, anticipated payer coverage, the Company’s strategic repositioning and path to operational profitability, potential use of milestone and royalty payments, and the Company’s ability to successfully commercialize Rebyota and Clenpiq. Forward-looking statements are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company’s control and cannot be predicted or quantified, and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. 

[i] Akorful RAA, Odoom A, Awere-Duodu A, Donkor ES. The Global Burden of Clostridioides difficile Infections, 2016-2024: A Systematic Review and Meta-Analysis. Infect Dis Rep. 2025 Apr 14;17(2):31. doi: 10.3390/idr17020031. PMID: 40277958; PMCID: PMC12026862.

[ii] Lessa FC, Mu Y, Bamberg WM, Beldavs ZG, Dumyati GK, Dunn JR, Farley MM, Holzbauer SM, Meek JI, Phipps EC, Wilson LE, Winston LG, Cohen JA, Limbago BM, Fridkin SK, Gerding DN, McDonald LC. Burden of Clostridium difficile infection in the United States. N Engl J Med. 2015 Feb 26;372(9):825-34. doi: 10.1056/NEJMoa1408913. PMID: 25714160; PMCID: PMC10966662.

[iii] Feuerstadt P, Theriault N, Tillotson G. The burden of CDI in the United States: a multifactorial challenge. BMC Infect Dis. 2023 Mar 7;23(1):132. doi: 10.1186/s12879-023-08096-0. PMID: 36882700; PMCID: PMC9990004.

[iv] Khanna S, Assi M, Lee C, et al. Efficacy and safety of RBX2660 in PUNCH CD3, a phase III, randomized, double-blind, placebo-controlled trial with a Bayesian primary analysis for the prevention of recurrent Clostridioides difficile infection. Drugs. 2022;82(15):1527-1538. doi:10.1007/s40265-022-01797-x.

[v] Data on file. Ferring Pharmaceuticals

[vi] MarketScan Commercial Claims and Encounters and Medicare Supplemental database

Contact

Chief Corporate and BD Officer
Adi Frish
RedHill Biopharma
adi@redhillbio.com

About Author

Cloud PR Wire

See author's posts

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.

Continue Reading

Press Release

RISE Robotics Awarded $100,000 MassVentures Grant to Accelerate Commercialization of Beltdraulic Technology

Published

32 minutes ago

on

September 1, 2026

By

Somerville, Massachusetts, USA, September 1st, 2026, FinanceWire

RISE Robotics, a developer of electric actuation technology for heavy machinery and defense applications, today announced that it has been awarded a $100,000 START Grant from MassVentures, a competitive, non-dilutive program of the Commonwealth of Massachusetts supporting the commercialization of advanced technologies. As a Stage I awardee, RISE is also eligible to compete for up to $800,000 in total START funding as it advances through subsequent stages of the program.

The award provides additional support for RISE’s efforts to expand commercialization of its Beltdraulic technology. Beltdraulic is a high-force electric actuation system designed to replace traditional hydraulic systems with a fluid-free architecture, delivering hydraulic-class force with greater digital control, improved efficiency, and precision.

Hydraulics have been a foundational technology in heavy machinery for decades, powering equipment ranging from construction machinery to agricultural and industrial systems. RISE is developing an alternative architecture based on electric motors, belts, and pulleys that is designed to deliver high force without hydraulic fluid.

The MassVentures START award adds to RISE’s growing track record of government-backed technology development.

In February 2026, RISE received a $3 million U.S. Air Force Tactical Funding Increase (TACFI) award to advance SuperJammer, its fluid-free munitions handling system, toward testing and evaluation. SuperJammer applies RISE’s electric actuation technology to demanding defense environments where precision, reliability, and the elimination of hydraulic fluid can provide significant advantages.

The two programs support complementary stages of RISE’s commercialization strategy. The Air Force award supports development and productization of the technology for defense applications, while the MassVentures START Grant supports efforts to translate the underlying technology into broader commercial markets.

“This award is a strong validation of the progress we’ve made translating advanced engineering into real-world systems,” said Hiten Sonpal, CEO of RISE Robotics. “Massachusetts continues to be an important partner in helping companies like ours move from breakthrough technology to commercial deployment.”

RISE is targeting the broader heavy machinery market, where the company estimates the opportunity at approximately $750 billion. Its Beltdraulic platform is designed to enable equipment manufacturers to replace conventional hydraulic systems with electric actuation while also creating a foundation for digital control, teleoperation, and autonomous operation.

RISE Robotics has generated more than $9 million in total revenue to date and is currently conducting a Regulation Crowdfunding offering that is open to both accredited and non-accredited investors.

About the MassVentures START Program

The START Grant Program, administered by MassVentures, provides non-dilutive funding to Massachusetts-based companies with active SBIR/STTR Phase II awards. The program is designed to help companies transition federally funded innovations toward commercialization, product development, and job creation within the Commonwealth.

About RISE Robotics

RISE Robotics is a deep technology company developing electric actuation systems for the heavy machinery and defense markets. Its flagship Beltdraulic technology uses a belt-and-pulley architecture to deliver high-force linear motion without hydraulic fluid.

RISE’s technology is designed to provide a pathway from conventional hydraulic systems to electric, digitally controlled machinery, with potential applications across construction, agriculture, industrial equipment, and defense.

RISE has generated more than $9M in total revenue and is a Reg CF company, allowing both accredited and non-accredited investors to own a piece of its innovative technology.

riserobotics.com

Contact

Lauren Damon
RISE Robotics
lauren@riserobotics.com
(617) 863-2521

About Author

Cloud PR Wire

See author's posts

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.

Continue Reading

Press Release

TrendEadvisor Launches Global Multi-Asset Platform Combining Online Investing with Social Trading

Published

32 minutes ago

on

September 1, 2026

By

Montreal, Canada, September 1st, 2026, FinanceWire

Launching September 1, 2026, the fintech platform will provide access to stocks, ETFs, commodities, forex, and other financial assets, supported by social and copy-trading tools.

TrendEadvisor.com today announced the official launch of its online trading and investment platform, designed to make participation in global financial markets more accessible, connected and easier to navigate.

The platform brings multiple asset classes into one digital environment, allowing users to explore opportunities across stocks, exchange-traded funds, cryptocurrencies, commodities, forex and other financial instruments. Instead of moving between disconnected services, TrendEadvisor gives users one place to research markets, monitor activity and manage their investment decisions.

At the centre of the platform is a social trading experience built around observation, transparency and shared market knowledge. Users can follow experienced investors, review their trading activity and see how different approaches respond to changing market conditions.

TrendEadvisor also includes copy-trading functionality, enabling users to automatically replicate selected trades from investors they choose to follow. This feature lets you engage with established strategies while keeping control over your account settings and investment decisions.

“Financial markets can feel unnecessarily complicated, particularly for people entering them for the first time,” said Linda Bouchard, spokesperson for TrendEadvisor. “We created TrendEadvisor to bring market access, investment tools and the human side of trading into one clear experience. Users can explore independently, learn from others and decide how actively they want to participate.”

Interest in online investing has expanded as individuals seek greater control over how they access and understand financial markets. At the same time, the growing number of instruments, platforms and sources of information has made the process increasingly fragmented.

TrendEadvisor.com aims to reduce that friction by combining broad market access with tools that help users discover, compare and follow different investment approaches.

The platform has been developed for a wide range of users, from people beginning to explore investing to experienced market participants looking for a connected multi-asset environment. Its interface brings together portfolio information, market data and social trading features across compatible devices.

Users can browse financial assets, monitor market movements and follow investor profiles based on their interests and objectives. The platform’s social features provide additional context around market activity, helping users move beyond isolated price charts and see how other participants approach opportunities and risk.

Copy trading does not remove the risks associated with investing. Market conditions can change quickly, and the previous performance of an investor or strategy does not guarantee future results. TrendEadvisor encourages users to understand the financial instruments they select, consider their personal circumstances and make decisions that reflect their individual tolerance for risk.

The launch reflects a broader change in financial technology. Investors increasingly expect platforms to offer more than access to transactions. They also want useful information, intuitive technology and opportunities to learn from wider communities.

“Our goal is not to tell people what to trade,” Bouchard added. “It is to give them a more informed and connected way to participate. Technology should make financial markets easier to understand without hiding the fact that every investment decision involves risk.”

TrendEadvisor will officially launch on September 1, 2026. Product availability, financial instruments and platform features may vary according to each user’s jurisdiction and applicable requirements.

For further information, visit https://trendeadvisor.com.

About TrendEadvisor

TrendEadvisor is a global fintech company providing an online trading and investment platform for access to stocks, ETFs, cryptocurrencies, commodities, forex and other financial assets.

The platform combines multi-asset market access with social trading and copy-trading functionality, enabling users to follow experienced investors and automatically replicate selected trading activity. TrendEadvisor is focused on creating a more accessible, connected and informed investing experience.

Contact

Press Release Responsable
Linda Bouchard
support@trendadvisor.com

About Author

Cloud PR Wire

See author's posts

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.

Continue Reading

LATEST POST

Like Us
Follow Us
Subscribe Us
Follow Us